Media
Focus on the development of new antibody drugs for the treatment of tumors and autoimmune inflammatory diseases

Media

新闻动态
/
/
China IND application of"Recombinant anti-human IL-17A/F humanized monoclonal antibody injection"for AS indication is accepted by CDE

China IND application of"Recombinant anti-human IL-17A/F humanized monoclonal antibody injection"for AS indication is accepted by CDE

  • Categories:News
  • Author:
  • Origin:
  • Time of issue:2020-12-22 16:21
  • Views:

(Summary description)China IND application of"Recombinant anti-human IL-17A/F humanized monoclonal antibody injection"for AS indication is accepted by CDE

China IND application of"Recombinant anti-human IL-17A/F humanized monoclonal antibody injection"for AS indication is accepted by CDE

(Summary description)China IND application of"Recombinant anti-human IL-17A/F humanized monoclonal antibody injection"for AS indication is accepted by CDE

  • Categories:News
  • Author:
  • Origin:
  • Time of issue:2020-12-22 16:21
  • Views:
Information

China IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” for AS indication is accepted by CDE

Scan the QR code to read on your phone

Previous: None
Next: None
Previous: None
Next: None
这是描述信息

Add

Zhong Guancun Biopharmaceutical Park, NO.5 Kaituo Road,

Haidian District, Beijing City, China, 10084

A1 Northern Building, 218 Xinghu St. Suzhou Industrial Park, Jiangsu Province, China, 215123

COPYRIGHT @2020 Suzhou xinkanghe Biomedical Technology Co., Ltd   京ICP备12345678   Power by 300.cn Beijing

这是描述信息

Follow us